Colombia launches first CAR-T trial for Hard-to-Treat blood cancers

This study aims to bring CAR-T cell therapy to Colombia for people with certain blood cancers that have come back or not responded to treatment. It has two parts: first, setting up the necessary partnerships and facilities to produce the therapy locally, and second, testing the safety of a custom-made CAR-T product called ARI-0001 in 12 adults. Participants will receive their own modified immune cells and be monitored closely for side effects and response for up to 15 years.